Virginia Holmes Appointed Non-Executive Director
Virginia Holmes Appointed as Non-Executive Director
21 December 2020
Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life sciences, announces the appointment of Virginia Holmes as a Non-Executive Director with effect from 1 January 2021.
Virginia has extensive knowledge of the financial services industry including investment management and banking. She was previously Chief Executive of AXA Investment Managers UK and held a number of senior leadership roles over more than a decade at Barclays Bank Group.
Virginia also brings a wide range of Board experience, both with UK listed companies and organisations across various jurisdictions. She is currently a Non-Executive Director of Intermediate Capital Group plc, a FTSE 100 specialist asset manager, and of the European Opportunities Trust plc, a closed ended European equity fund. She is also Chair of USS Investment Management Ltd, the fiduciary manager of Universities Superannuation Scheme Ltd.
Melanie Gee, Chair of Syncona Limited, said: "We are pleased to strengthen our Board of Directors with the appointment of Virginia. She has extensive experience and a proven track record of working with investment businesses as they look to develop and expand. Her expertise will be invaluable as we look to manage and grow a sustainable portfolio of leading life science companies."
Virginia Holmes said: "I am very much looking forward to joining Syncona's Board and working with their expert life science investment team, to support them in accelerating the growth of the business and delivering the purpose to invest to extend and enhance human life."
No further details are required to be disclosed under LR 9.6.13.
Tel : +44 (0) 20 3981 7940
Ben Atwell / Natalie Garland-Collins / Tim Stamper
Tel: +44 (0) 20 3727 1000
Syncona (LON: SYNC) is a healthcare company focused on founding, building and funding a portfolio of global leaders in life science. Our purpose is to invest to extend and enhance human life. We do this by founding and building companies to deliver transformational treatments to patients in areas of high unmet need.
Our strategy is to found, build and fund companies around exceptional science to create a dynamic portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our strategic balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or few treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.